BioCentury
ARTICLE | Company News

Abbott licenses anti-CD4 antibody from Biotest

June 22, 2011 12:56 AM UTC

Biotest AG (Xetra:BIO) granted Abbott Laboratories (NYSE:ABT) exclusive, worldwide rights to develop and commercialize BT-061, a humanized mAb against CD4 in Phase II testing for rheumatoid arthritis ...